Idera Pharmaceuticals, Inc.

Quick facts

Phase 2 pipeline

• IMO-2125 · Oncology
  IMO-2125 is a synthetic oligonucleotide that acts as a TLR9 agonist, stimulating the innate immune system.
• IMO-8400 Regimen 1
• IMO-8400 Regimen 2 · Immunology
  IMO-8400 is a small molecule inhibitor of IRAK4, a key kinase in the Toll-like receptor signaling pathway.
• IMO-8400 Regimen 3
• IMO-8400 Regimen 4

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Idera Pharmaceuticals, Inc. portfolio CI brief
• Idera Pharmaceuticals, Inc. pipeline updates RSS